Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Amur Minerals ( (GB:CRTX) ) is now available.
CRISM Therapeutics Corporation has announced its final audited results for the year ended December 2024, highlighting significant progress since joining AIM in May 2024. The company has strengthened its IP position with a new EU patent for ChemoSeed, secured additional revenues through a service agreement, and received positive scientific advice from the MHRA, which confirmed no further toxicology studies are needed, saving £400,000. CRISM is poised to submit a clinical trial application for ChemoSeed in glioblastoma and has initiated research for prostate cancer, supported by an Innovate UK grant. The company’s progress and strategic milestones, including the upcoming phase II clinical trial, position it confidently for future growth.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based innovative drug delivery company focused on improving cancer treatment for solid tumors through localized chemotherapy delivery. Their lead product, ChemoSeed, is designed to enhance the clinical performance of chemotherapy drugs by directly implanting them into tumors or resection margins, particularly targeting glioblastoma.
Average Trading Volume: 65,147
Technical Sentiment Signal: Strong Buy
Current Market Cap: £1.78M
For a thorough assessment of CRTX stock, go to TipRanks’ Stock Analysis page.